克雷森特生物制药

最新新闻

• 评级变动
  LifeSci Capital Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $22
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• 评级变动
  Piper Sandler Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/6/23
• 评级变动
  TD Cowen Maintains Crescent Biopharma(CBIO.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $28
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• 评级变动
  Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Cuts Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/5/1
• H.C. Wainwright Upgrades Crescent Biopharma(CBIO.US) to Buy Rating, Announces Target Price $36
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• 评级变动
  Guggenheim Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• 公司公告
  Catalyst Biosciences: Catalyst Biosciences, Inc. - Cash Distribution and Exercise Consideration Option Symbol: CBIO
  OCC · 2022/12/30
• 公司公告
  Catalyst Biosciences: Catalyst Biosciences, Inc. - Reverse Split and Name/Symbol/CUSIP Change Option Symbol: CBIO New Symbol: GYRE1
  OCC · 2023/10/31
• 评级变动
  H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $22
  \u5e02\u573a\u8d44\u8baf · 2026/5/4
• 评级变动
  Wedbush Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $27
  \u5e02\u573a\u8d44\u8baf · 2026/6/1
• 公司公告
  Catalyst Biosciences: Catalyst Biosciences, Inc. - Reverse Split and Name/Symbol/CUSIP Change Option Symbol: CBIO New Symbol: GYRE1
  OCC · 2023/10/31
• 评级变动
  H.C. Wainwright Downgrades Crescent Biopharma(CBIO.US) to Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/1
• 公司公告
  Catalyst Biosciences: Catalyst Biosciences, Inc. - Cash Distribution and Exercise Consideration Option Symbol: CBIO
  OCC · 2022/12/30
• LifeSci Capital Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $28
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/6/23
• 评级变动
  H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Cuts Target Price to $22
  \u5e02\u573a\u8d44\u8baf · 2026/3/2
• 评级变动
  Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Sionna Therapeutics, Inc. (SION) and Crescent Biopharma (CBIO)
  TipRanks · 2026/6/23
• 评级变动
  A Quick Look at Today's Ratings for Crescent Biopharma(CBIO.US), With a Forecast Between $27 to $35
  \u5e02\u573a\u8d44\u8baf · 2026/4/30

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。